Drugs / Vebrekotuzumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07403136 | Apr 2026 → Aug 2027 expected | esophageal squamous cell carcinoma | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vebrekotuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07403136 ↗ |
| Action | Deplete | “cell-killing drug directly to the cancer cells, aiming to destroy them” NCT07403136 ↗ |
| Target | EGFR | “designed to target a specific protein called EGFR” NCT07403136 ↗ |